Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MET-2 in mild to moderate ulcerative colitis
NCT03832400Phase 1Completed
- Sponsor
- NuBiyota
- Start
- Feb 2019
- Primary completion
- Mar 2020
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MET-2 in ulcerative colitis (UC) (3 arms), sponsored by NuBiyota. Primary endpoint: Gut Microbiome restoration at Day 42. Started Feb 2019; status: completed.
02
Drugs
MET-2
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03832400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03832400.